Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Journal Editors Press For More Disclosure Of Underlying Trial Data

This article was originally published in The Gray Sheet

Executive Summary

The International Committee of Medical Journal Editors is collecting feedback on its plan to require clinical trial investigators to disclose patient-level data as a condition of publication.

You may also be interested in...



Clinical Trial Transparency Gets A Boost With J&J Agreement, IOM Report

Johnson & Johnson's device and diagnostic clinical trial data is now available to independent researchers via Yale University’s Open Data Access (YODA) Project, announced the same day as an Institute of Medicine report mapping out strategies for clinical trial data-sharing.

Infuse Open-Access Project A Model For The Future? Medtronic Thinks So

Two independent analyses published last week on Medtronic’s Infuse biologic bone graft do not paint a positive picture for the device, but they do represent an important model for the future of open-access data analysis, both Medtronic and academic proponents say.

BrainStorm’s NurOwn Gets Many, Many Thumbs Down From US FDA Panel

In overwhelmingly concluding that efficacy has not been demonstrated for the mesenchymal stromal cell therapy, panelists went beyond just the failed Phase III trial and cited BrainStorm’s ‘statistical magic’ and failure to adequately describe the mechanism of action, as well as safety and product quality concerns.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034918

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel